Search Results

U.S. Naval Infectious Diseases Diagnostic Laboratory to study dengue fever activity of Claromer antiviral compounds, combatting a rapidly growing mosquito-borne viral infection and a national priority biodefense threat

U.S. Army Institute of Surgical Research to conduct key studies intended to further our knowledge of the effects of Claromer technology

Appointment of José Antonio Alas brings more than 30 years of biotech expertise, including global business development, international partnerships, patient access to innovative medications and product launches as the company advances its Claromer drug discovery platform

Austin, Texas--(Newsfile Corp. - May 15, 2024) - Maxwell Biosciences, Inc, a pre-clinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides...

Austin, Texas--(Newsfile Corp. - May 8, 2024) - Maxwell Biosciences, a preclinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides based on its patented Claromer® technology platform...

Maxwell Biosciences (“Maxwell”), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors.

Maxwell Biosciences, Inc., (MXB) a pre-clinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides based on its patented Claromer® technology platform

Maxwell Biosciences, a pioneering preclinical drug platform company, today announced publication of a revolutionary mechanism of action study for their Claromer® compounds in the journal ACS Infectious Diseases.

Maxwell Biosciences (“Maxwell”), a preclinical drug discovery platform company focused on the development of synthetic compounds that mimic existing human biomolecules (biomimetic therapeutics) from our innate immune system, today announced the appointment of Maxie McFarland, MBA, as Senior Vice President of Corporate Development and Investor Relations.